Skip to main content
Top
Published in: Indian Journal of Gastroenterology 5/2011

01-09-2011 | Original Article

Pulmonary manifestations in inflammatory bowel disease: a prospective study

Authors: Devendra Desai, Samir Patil, Zarir Udwadia, Shailendra Maheshwari, Philip Abraham, Anand Joshi

Published in: Indian Journal of Gastroenterology | Issue 5/2011

Login to get access

Abstract

Background

Although pulmonary abnormalities have been recognized in patients with inflammatory bowel diseases (IBD), their prevalence and clinical significance are not known.

Aim

To study the prevalence and clinical significance of pulmonary abnormalities in patients with IBD.

Methods

Ninety-five non-consecutive patients with IBD (12 Crohn’s disease, 83 ulcerative colitis; mean age 41.9 [SD 13] years; 47 women) were prospectively studied from January 2007 to March 2010. Pulmonary function tests (PFT) and high-resolution CT (HRCT) chest were performed in them. PFT were compared to those in 270 healthy (control) subjects matched for age, sex and smoking status.

Results

Twenty-seven (28.5%) patients and 11 (4%) control subjects had abnormal PFT (p < 0.0001). Small airway obstruction was seen in 18 patients, restrictive defect in six and mixed defect in three. Twenty-one (22%) patients had abnormal HRCT findings – bronchiectasis and nodules (nine patients each, including one with nodules who later developed active tuberculosis after infliximab therapy), parenchymal bands (8), mediastinal lymphadenopathy (five, including two with tuberculosis on histology and culture), emphysema (5), brochiolitis (2), pleural effusion or thickening (2), pericardial effusion (2), patchy consolidation (1), ground-glass opacities (1) and lung metastasis (1). Three patients had symptoms (one asthma, two cough).

Conclusion

PFT and HRCT chest showed abnormality in about one-quarter of patients with IBD. A majority of patients with these abnormalities were asymptomatic.
Literature
1.
go back to reference van Lierop PP, Samsom JN, Escher JC, et al. Role of the innate immune system in the pathogenesis of inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:142–51.PubMedCrossRef van Lierop PP, Samsom JN, Escher JC, et al. Role of the innate immune system in the pathogenesis of inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:142–51.PubMedCrossRef
2.
go back to reference Higenbottam T, Cochrane GM, Clark TJ, et al. Bronchial disease in ulcerative colitis. Thorax. 1980;35:581–5.PubMedCrossRef Higenbottam T, Cochrane GM, Clark TJ, et al. Bronchial disease in ulcerative colitis. Thorax. 1980;35:581–5.PubMedCrossRef
3.
go back to reference Kraft SC, Earle RH, Roesler M, et al. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med. 1976;136:454–9.PubMedCrossRef Kraft SC, Earle RH, Roesler M, et al. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med. 1976;136:454–9.PubMedCrossRef
4.
go back to reference Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest. 2007;131:524–32.PubMedCrossRef Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest. 2007;131:524–32.PubMedCrossRef
5.
go back to reference Tzanakis NE, Tsiligianni IG, Siafakas NM. Pulmonary involvement and allergic disorders in inflammatory bowel disease. World J Gastroenterol. 2010;16:299–305.PubMedCrossRef Tzanakis NE, Tsiligianni IG, Siafakas NM. Pulmonary involvement and allergic disorders in inflammatory bowel disease. World J Gastroenterol. 2010;16:299–305.PubMedCrossRef
6.
go back to reference Mahadeva R, Walsh G, Flower CD, et al. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J. 2000;15:41–8.PubMedCrossRef Mahadeva R, Walsh G, Flower CD, et al. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J. 2000;15:41–8.PubMedCrossRef
7.
go back to reference Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819–31.PubMed Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819–31.PubMed
8.
go back to reference Songur N, Songur Y, Tuzun M, et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol. 2003;37:292–8.PubMedCrossRef Songur N, Songur Y, Tuzun M, et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol. 2003;37:292–8.PubMedCrossRef
9.
go back to reference Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore). 1993;72:151–83. Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore). 1993;72:151–83.
10.
go back to reference Tzanakis N, Bouros D, Samiou M, et al. Lung function in patients with inflammatory bowel disease. Respir Med. 1998;92:516–22.PubMedCrossRef Tzanakis N, Bouros D, Samiou M, et al. Lung function in patients with inflammatory bowel disease. Respir Med. 1998;92:516–22.PubMedCrossRef
11.
go back to reference Casey MB, Tazelaar HD, Myers JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol. 2003;27:213–9.PubMedCrossRef Casey MB, Tazelaar HD, Myers JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol. 2003;27:213–9.PubMedCrossRef
12.
go back to reference Parry SD, Barbatzas C, Peel ET, et al. Sulphasalazine and lung toxicity. Eur Respir J. 2002;19:756–64.PubMedCrossRef Parry SD, Barbatzas C, Peel ET, et al. Sulphasalazine and lung toxicity. Eur Respir J. 2002;19:756–64.PubMedCrossRef
13.
go back to reference Herrlinger KR, Noftz MK, Dalhoff K, et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol. 2002;97:377–81.PubMedCrossRef Herrlinger KR, Noftz MK, Dalhoff K, et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol. 2002;97:377–81.PubMedCrossRef
14.
go back to reference Tunc B, Filik L, Bilgic F, et al. Pulmonary function tests, high-resolution computed tomography findings and inflammatory bowel disease. Acta Gastroenterol Belg. 2006;69:255–60.PubMed Tunc B, Filik L, Bilgic F, et al. Pulmonary function tests, high-resolution computed tomography findings and inflammatory bowel disease. Acta Gastroenterol Belg. 2006;69:255–60.PubMed
15.
go back to reference Sarioglu N, Turkel N, Sakar A, et al. Lung involvement in inflammatory bowel diseases. Ann Saudi Med. 2006;26:407–8.PubMed Sarioglu N, Turkel N, Sakar A, et al. Lung involvement in inflammatory bowel diseases. Ann Saudi Med. 2006;26:407–8.PubMed
16.
go back to reference Sethy PK, Dutta U, Aggrawal AN, et al. Pulmonary and hematological alterations in idiopathic ulcerative colitis. Indian J Gastroenterol. 2003;22:176–9.PubMed Sethy PK, Dutta U, Aggrawal AN, et al. Pulmonary and hematological alterations in idiopathic ulcerative colitis. Indian J Gastroenterol. 2003;22:176–9.PubMed
17.
go back to reference Yilmaz A, Yilmaz Demirci N, Hosgün D, et al. Pulmonary involvement in inflammatory bowel disease. World J Gastroenterol. 2010;16:4952–7.PubMedCrossRef Yilmaz A, Yilmaz Demirci N, Hosgün D, et al. Pulmonary involvement in inflammatory bowel disease. World J Gastroenterol. 2010;16:4952–7.PubMedCrossRef
Metadata
Title
Pulmonary manifestations in inflammatory bowel disease: a prospective study
Authors
Devendra Desai
Samir Patil
Zarir Udwadia
Shailendra Maheshwari
Philip Abraham
Anand Joshi
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Indian Journal of Gastroenterology / Issue 5/2011
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-011-0129-1

Other articles of this Issue 5/2011

Indian Journal of Gastroenterology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.